Intrauterine baclofen exposure: a multidisciplinary approach.
Maternal use of the antispasmodic baclofen during pregnancy is an uncommon clinical scenario and leads to uncertainty regarding neonatal risks. We present a team-based, peripartum management plan designed for safe monitoring and minimizing the risk of neonatal withdrawal after unusual drug exposure. Incorporating the expertise of neonatology, nursing, pharmacy, neurology, and the lactation service, as well as parental input, this consensus approach was implemented in a case of maternal oral baclofen use with a successful outcome for the infant and family.
Moran
Lisa R
LR
Department of Pharmacy-GB005, Massachusetts General Hospital, 55 Fruit St, Boston, Massachusetts 02114, USA. lrmoran@partners.org
Almeida
Pamela G
PG
Worden
Susan
S
Huttner
Kenneth M
KM
D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use; D001418:Baclofen / Q000009:adverse effects* / Q000627:therapeutic use; D001942:Breast Feeding; D005260:Female; D018755:GABA Agonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D009125:Muscle Relaxants, Central / Q000009:adverse effects* / Q000627:therapeutic use; D010098:Oxycodone / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D012019:Reflex Sympathetic Dystrophy / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control*
D000701:Analgesics, Opioid; D018755:GABA Agonists; D009125:Muscle Relaxants, Central; D010098:Oxycodone; D001418:Baclofen